Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses
Open Access
- 26 August 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 6 (8) , e1001079
- https://doi.org/10.1371/journal.ppat.1001079
Abstract
Influenza viruses resistant to antiviral drugs emerge frequently. Not surprisingly, the widespread treatment in many countries of patients infected with 2009 pandemic influenza A (H1N1) viruses with the neuraminidase (NA) inhibitors oseltamivir and zanamivir has led to the emergence of pandemic strains resistant to these drugs. Sporadic cases of pandemic influenza have been associated with mutant viruses possessing a histidine-to-tyrosine substitution at position 274 (H274Y) in the NA, a mutation known to be responsible for oseltamivir resistance. Here, we characterized in vitro and in vivo properties of two pairs of oseltaimivir-sensitive and -resistant (possessing the NA H274Y substitution) 2009 H1N1 pandemic viruses isolated in different parts of the world. An in vitro NA inhibition assay confirmed that the NA H274Y substitution confers oseltamivir resistance to 2009 H1N1 pandemic viruses. In mouse lungs, we found no significant difference in replication between oseltamivir-sensitive and -resistant viruses. In the lungs of mice treated with oseltamivir or even zanamivir, 2009 H1N1 pandemic viruses with the NA H274Y substitution replicated efficiently. Pathological analysis revealed that the pathogenicities of the oseltamivir-resistant viruses were comparable to those of their oseltamivir-sensitive counterparts in ferrets. Further, the oseltamivir-resistant viruses transmitted between ferrets as efficiently as their oseltamivir-sensitive counterparts. Collectively, these data indicate that oseltamivir-resistant 2009 H1N1 pandemic viruses with the NA H274Y substitution were comparable to their oseltamivir-sensitive counterparts in their pathogenicity and transmissibility in animal models. Our findings highlight the possibility that NA H274Y-possessing oseltamivir-resistant 2009 H1N1 pandemic viruses could supersede oseltamivir-sensitive viruses, as occurred with seasonal H1N1 viruses. Although most of the currently circulating 2009 pandemic influenza A (H1N1) viruses are susceptible to neuraminidase (NA) inhibitors (oseltamivir and zanamivir), oseltamivir-resistant mutants have sporadically appeared. Yet, the pathogenicity and transmissibility of these oseltamivir-resistant 2009 H1N1 pandemic viruses remain unknown. Here, we compared the pathogenicity and transmissibility of two pairs of oseltamivir-sensitive and -resistant viruses in mouse and ferret models. We found that the oseltamivir-resistant viruses efficiently replicated in the lungs of mice treated with oseltamivir or even zanamivir. Further, we demonstrated that these oseltamivir-resistant viruses caused lung lesions in ferrets and efficiently transmitted between ferrets, as did their oseltamivir-sensitive counterparts. Overall, our results suggest the possibility that oseltamivir-resistant viruses could spread among humans without loss of pathogenicity.Keywords
This publication has 28 references indexed in Scilit:
- Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In VitroPLOS ONE, 2010
- Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase InhibitorsJAMA, 2007
- Comparative Activities of Oseltamivir and A‐322278 in Immunocompetent and Immunocompromised Murine Models of Influenza Virus InfectionThe Journal of Infectious Diseases, 2006
- Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variantsAntiviral Research, 2006
- Isolation of drug-resistant H5N1 virusNature, 2005
- Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemicJournal of Antimicrobial Chemotherapy, 2005
- Neuraminidase Inhibitor-Rimantadine Combinations Exert Additive and Synergistic Anti-Influenza Virus Effects in MDCK CellsAntimicrobial Agents and Chemotherapy, 2004
- Resistant influenza A viruses in children treated with oseltamivir: descriptive studyPublished by Elsevier ,2004
- Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant VariantsAntimicrobial Agents and Chemotherapy, 2001
- Influenza virus neuraminidase inhibitorsThe Lancet, 2000